LivaNova PLC (LIVN) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
LivaNova PLC
Address
20 Eastbourne Terrace
London, W2 6LG
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 3325 0660
Website
Sector
Healthcare
Industry
Medical - Devices
Employees
2900
First IPO Date
October 19, 2015
Key Executives
| Name | Title | Pay | Year Born |
| Vladimir A. Makatsaria | Chief Executive Officer & Director | 2.37M | 1973 |
| Ahmet Tezel | Chief Innovation Officer | 1.07M | 1975 |
| Natalia Kozmina | Chief Human Resources Officer | 1.09M | 1972 |
| Alex Shvartsburg | Chief Financial Officer | 1.12M | 1970 |
| Franco Poletti | President of Cardiopulmonary Business Unit | 1.13M | N/A |
| John Webb | Vice President of Sleep Apnea and Epilepsy | 0 | N/A |
| Paul R. Buckman | President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement | 0 | 1956 |
| Philip Kowalczyk | Chief Strategy & Corporate Development Officer | 0 | N/A |
| Deanna Wilke | Vice President of Corporate Communications | 0 | N/A |
| Sujay Mashru | Senior Vice President of APAC & Growth Markets | 0 | N/A |
| Lindsey Little | VP & Chief Accounting Officer | 0 | N/A |
| Lucile Blaise | Global Head of Commercialization - Obstructive Sleep Apnea (OSA) | 0 | 1971 |
| Stephanie Bolton | President of Global Epilepsy | 0 | 1982 |
| Briana Gotlin | Vice President of Investor Relations | 0 | N/A |
| Sarah Mohr | Secretary | 0 | N/A |
Description
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
